Seeking Alpha EN

Sarepta Therapeutics Non-GAAP EPS of -$3.58 misses by $2.81, revenue of $443M beats by $52.05M

Feb 25, 2026 &02142525202628; 21:14 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -60/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Sarepta Therapeutics ha annunciato risultati finanziari non GAAP per l'EPS di -3,58 dollari, che hanno mancato le aspettative di -2,81 dollari, mentre i ricavi di 443 milioni di dollari hanno superato le aspettative di 52,05 milioni di dollari.

AI CONFIDENCE

80% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

SRPT

SRPTStock

Expected to decline

Risultati finanziari non GAAP deludenti

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

I trader dovrebbero considerare di vendere le azioni di Sarepta Therapeutics a causa dei risultati finanziari deludenti e della mancata aspettativa EPS.

KEY SIGNALS

Risultati finanziari deludentiMancata aspettativa EPS

SECTORS INVOLVED

BiotecnologieFarmaceutici

Analysis generated on Feb 26, 2026 at 04:40 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Sarepta Therapeutics Non-GAAP EPS of -$3.58 misses by $2.81, revenue of $443M beats by $52.05M

RELATED INTELLIGENCE